Waverley Lists In Frankfurt
Oncology Specialist Cross-Lists On Frankfurt Stock Exchange
Canadian generic oncology specialist Waverley Pharma has cross-listed on the Frankfurt Stock Exchange.
You may also be interested in...
Waverley is evaluating options for its generics as it looks likely to throw its all at the company’s lead product candidate in the hopes of luring a development partner or buyer.
Having made its entry into the UK oncology generics market late last year with capecitabine and temozolomide, Canada’s Waverley Pharma now has clearance to add erlotinib tablets to its portfolio.
Canada’s Waverley Pharma has acquired two UK oncology generics, capecitabine and temozolomide, from Reliance Life Sciences. “The products were developed by Reliance Life Sciences and the binding contracts with the UK National Health Service (NHS) for the supply of these products are being transferred to Waverley Pharma,” the firm noted.